In line with previously announced plans to diversify its portfolio, Novo Nordisk A/S has entered into a collaboration with a university spin-out, Embark Biotech ApS, to discover new treatments for obesity and associated metabolic pathologies. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
